depression. Major depressive disorder, recurrent, unspecified
Conditions
Interventions
Intervention group: Intervention group: receiving 0.5mg/kg ketamine as a single intravenous dose - Rotex medica trittau germany.
Sponsors
Vice Chancellor for Research and Technology, Shahrood Islamic Azad University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with treatment-resistant major depressive disorder based on DSM IV _ TR criteria Being in a depressive episode Failure to respond to antidepressants and shock medications and failure to control symptoms with other methods Intolerance of oral antidepressants
Exclusion criteria
Exclusion criteria: More serious psychiatric disorders: bipolar 1 and 2 - cyclothymia - psychosis - obsession - ski and affective Addiction or withdrawal from drugs Personality disorder Physical diseases such as: thyroid disorders, diabetes, hypertension, stroke, brain surgeries, etc. Response to drug treatment and control of disease symptoms with drugs Received ECT two months before starting ketamine treatment Receiving antidepressant medication one month before starting ketamine treatment Lack of consent to participate in the study Cardiovascular problems Pregnancy and breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression score in Beck and Hamilton test. Timepoint: Comparison of Hamilton and Beck test results before injection, two days after injection, one week after injection, one month after injection. Method of measurement: The criterion of response to ketamine treatment is a decrease of 50% or more in Beck and Hamilton tests. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad shiroudi
Islamic Azad University
Outcome results
None listed